Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otenabant in obese adults
NCT00396448Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Feb 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of otenabant in obesity (3 arms), sponsored by Pfizer. Primary endpoints: Change in body weight at 1 year and Proportion of subjects with 5% weight loss at 1 year. Started Feb 2007; status: terminated.
02
Drugs
otenabant
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00396448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396448.